Alexa Hetzel, PA-C, discusses the clinical efficacy of a non-steroidal topical JAK inhibitor that helps patients with vitiligo achieve significant facial repigmentation over 52 weeks. She emphasizes the importance of consistent twice-daily dosing and the provider’s role as a “cheerleader” to help patients manage the tedious repigmentation process and its impact on their mental health.
Tristan Hasbargen, PA-C, of Dermatology Associates of Tallahassee, discusses the treatment of Vitiligo, with a focus on helping patients develop realistic expectations for the repigmentation
David Rosmarin, MD, the chair of the Department of Dermatology at Indiana University in Indianapolis, discusses results from a pooled subgroup analysis of the 104-week
Dr. Desai discusses treatment strategies for patients with Vitiligo, focusing specifically on the use of Ruxolitinib> cream 1.5% for depigmented areas affecting the face and
Chantel Hillestad discusses the unique challenges involved in treating Vitiligo affecting the hands, an area that is often more resistant to repigmentation due to lower
Chantel Hillestad, RN, MSN, DCNP, FNP-C, shares clinical experience using ruxolitinib to restore pigmentation in vitiligo patients across all age groups. Topics Covered: Ruxolitinib for
Dr. Desai reviews findings from a post-hoc analysis of the TRuE-V1 and TRuE-V2 clinical trials, focusing on the efficacy and durability of treatment with Ruxolitinib>
Jennifer Silva discusses important safety considerations when treating patients with Vitiligo using JAK inhibitors, emphasizing the need for clear patient counseling regarding black box warnings
Dr. Seneschal provides an update on the evolving role of JAK inhibitors in the treatment of Vitiligo, reviewing both currently available topical therapies and investigational
Jennifer Silva, APRN-DNP, outlines treatment options for patients with vitiligo who have not responded well to traditional therapies. Topics Covered: Challenges in vitiligo treatment Strategies
Dr. Hamzavi and James Del Rosso, DO, Editor-in-Chief of Journal of Clinical and Aesthetic Dermatology, discuss practical treatment considerations for patients with Vitiligo using Ruxolitinib>
Dr. Rosmarin reviews key updates in the treatment of Vitiligo, expanding on topics presented during his session at the Masterclasses in Dermatology Meeting. His discussion
Gina Mangin discusses patient-centered strategies for managing Vitiligo, emphasizing the importance of encouragement, education, and ongoing motivation throughout the treatment journey. Her presentation highlights how
Gina Mangin, MPAS, PA-C, discusses the role of light box therapy in vitiligo management, with a focus on setting clear expectations around treatment timelines and
Shanna Miranti, MPAS, PA-C, discusses prescribing considerations for topical ruxolitinib in patients with vitiligo, emphasizing the importance of prior treatment attempts with topical corticosteroids and
Nada Elbuluk, MD, discusses the importance of assessing psychological comorbidities in patients with vitiligo by gathering key social information, including daily activities, living situation, and
